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Sphingolipids inhibit endosomal recycling of nutrient transporters
by inactivating ARF6
Brendan T. Finicle*, Manuel U. Ramirez*, Gang Liu, Elizabeth M. Selwan, Alison N. McCracken, Jingwen Yu,
Yoosun Joo, Jannett Nguyen, Kevin Ou, Saurabh Ghosh Roy, Victor D. Mendoza, Dania Virginia Corrales and
Aimee L. Edinger‡
ABSTRACT
Endogenous sphingolipids (ceramide) and related synthetic
molecules (FTY720, SH-BC-893) reduce nutrient access by
decreasing cell surface expression of a subset of nutrient
transporter proteins. Here, we report that these sphingolipids
disrupt endocytic recycling by inactivating the small GTPase ARF6.
Consistent with reported roles for ARF6 in maintaining the tubular
recycling endosome, MICAL-L1-positive tubules were lost from
sphingolipid-treated cells. We propose that ARF6 inactivation may
occur downstream of PP2A activation since: (1) sphingolipids that fail
to activate PP2A did not reduce ARF6-GTP levels; (2) a structurally
unrelated PP2A activator disrupted tubular recycling endosome
morphology and transporter localization; and (3) overexpression of
a phosphomimetic mutant of the ARF6GEFGRP1 prevented nutrient
transporter loss. ARF6 inhibition alone was not toxic; however, the
ARF6 inhibitors SecinH3 and NAV2729 dramatically enhanced
the killing of cancer cells by SH-BC-893 without increasing
toxicity to peripheral blood mononuclear cells, suggesting that
ARF6 inactivation contributes to the anti-neoplastic actions of
sphingolipids. Taken together, these studies provide mechanistic
insight into how ceramide and sphingolipid-like molecules limit
nutrient access and suppress tumor cell growth and survival.
KEY WORDS: Nutrient transporters, ARF6, Endosomal recycling,
Sphingolipids, GRP1
INTRODUCTION
Sphingolipids induce an evolutionarily conserved adaptive
quiescence program in stressed cells that depends on the
downregulation of nutrient transporters. Phytosphingosine starves
heat-stressed yeast into growth arrest by triggering the
internalization of several nutrient permeases, including the
tryptophan transporters TAT1 and TAT2, the uracil transporter
FUR4 and the general amino acid permease GAP1 (Bultynck et al.,
2006; Chung et al., 2001; Dickson et al., 1997; Skrzypek et al.,
1998; Welsch et al., 2004). In mammalian cells, ceramide produced
in response to a variety of stresses antagonizes growth and
proliferation, in part by downregulating nutrient transporter
proteins and reducing amino acid and glucose import (Guenther
et al., 2008, 2014; Hannun and Obeid, 2008; Summers et al.,
1998). Attributing cellular phenotypes to specific endogenous
sphingolipids is complicated by the fact that a large number of
enzymes rapidly metabolize sphingolipids into derivatives that can
have different, and even opposing, effects on cells (Hannun and
Obeid, 2008). Using synthetic, sphingolipid-like molecules can
help to overcome this problem. Similar to the endogenous
sphingolipids phytosphingosine and ceramide, the FDA-approved
sphingolipid drug FTY720 triggers transporter downregulation and
induces a starvation-like response in both yeast and mammalian
cells (Barthelemy et al., 2017; Romero Rosales et al., 2011; Welsch
et al., 2004). FTY720 is a pro-drug, and FTY720 phosphate
produced intracellularly is responsible for the therapeutic,
immunosuppressive actions via stimulation of sphingosine-1-
phosphate (S1P) receptors (Brinkmann et al., 2010).
Unphosphorylated FTY720, in contrast, limits tumor cell growth
and survival in vitro and in vivo by activating PP2A and disrupting
endocytic trafficking (Kim et al., 2016; Romero Rosales et al.,
2011). Unlike FTY720, the conformationally constrained FTY720
analog SH-BC-893 (893) does not activate S1P receptors, even in its
phosphorylated form (Chen et al., 2016; Kim et al., 2016; Perryman
et al., 2016). However, FTY720 and 893 produce identical
disruptions in intracellular trafficking, and their IC50 values are
closely matched, suggesting that effects on trafficking, not S1P
receptors, are responsible for the anti-cancer activity of FTY720
(Kim et al., 2016; Romero Rosales et al., 2011). FTY720 and 893
disrupt the trafficking of transporters for glucose (GLUT1, also
known as SLC2A1), pyruvate, lactate and acetate (MCT1, also
known as SLC16A1; MCT4, also known as SLC16A3), glutamine
(ASCT2, also known as SLC1A5) and leucine (LAT1, also known
as SLC7A5) (Barthelemy et al., 2017; Kim et al., 2016).
Downregulation of multiple mammalian nutrient transporters by
sphingolipids is consistent with the observation that both
phytosphingosine and FTY720 promote internalization of
permeases for multiple amino acids (tryptophan, leucine, histidine
and proline) and uracil in yeast (Barthelemy et al., 2017; Bultynck
et al., 2006; Chung et al., 2000, 2001; Skrzypek et al., 1998). In
summary, synthetic molecules like FTY720 and 893 phenocopy the
growth suppressive effects of endogenous sphingolipids on
endocytic trafficking while minimizing the confounding effects of
sphingolipid metabolism.
The molecular mechanism underlying sphingolipid-induced
nutrient transporter loss has been dissected in yeast.
Phytosphingosine triggers actin-dependent endocytosis of nutrient
transporters by inducing TORC2-dependent phosphorylation of the
pleckstrin-homology (PH) domain-containing proteins SLM1 and
SLM2 and RSP5-dependent ubiquitylation of the transporters
(Bultynck et al., 2006; Chung et al., 2000; Daquinag et al., 2007;
Fadri et al., 2005). Unfortunately, although sphingolipid-inducedReceived 21 November 2017; Accepted 21 May 2018
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transporter loss is conserved in mammalian cells, the molecular
details are not. We have thus far been unable to detect
ubiquitylation of nutrient transporters or a role for the RSP5
homolog NEDD4 in mammalian cells treated with FTY720 or
ceramide, and there are no clear mammalian orthologs of the SLM1
or SLM2 proteins that promote actin polarization, eisosome
organization and endocytic recycling in yeast (Douglas and
Konopka, 2014; Kamble et al., 2011; Olivera-Couto et al., 2011;
Walther et al., 2006). However, a DELTA-BLAST search against
the human proteome indicates that the PH domains of SLM1 and
SLM2 bear homology to the PH domains present in the ARF6 GAP
ACAP2 (centaurin β2) and in the cytohesin family of ARF6
GEFs [cytohesin-1, cytohesin-2 (ARNO), cytohesin-3 (GRP1),
cytohesin-4]. This similarity is interesting because ARF6
regulates actin dynamics, endocytosis and recycling, the same
processes controlled by the SLM proteins (Donaldson and Jackson,
2011; Schweitzer et al., 2011). Sphingolipids have not previously
been linked to ARF6 regulation. Rather, the available evidence
suggests that sphingolipids downregulate nutrient transporter
proteins in mammalian cells by activating the serine and
threonine protein phosphatase 2A (PP2A). Ceramide, FTY720
and 893 activate PP2A in vitro whereas dihydroceramide, a
sphingolipid that does not kill cells, does not (Chalfant et al., 2004;
Dobrowsky et al., 1993; Kim et al., 2016). PP2A activation is
necessary for sphingolipid-induced nutrient transporter loss, as
PP2A inhibition with calyculin A or SV40 small t antigen
expression maintains transporters on the cell surface in the
presence of ceramide, FTY720 or 893 (Guenther et al., 2008;
Kim et al., 2016; Romero Rosales et al., 2011). How PP2A
activation triggers transporter loss is not understood. Intriguingly,
many of the proteins that are downregulated by sphingolipids are
also cargo for the ARF6-dependent, clathrin-independent endocytic
trafficking pathway (Eyster et al., 2009; Maldonado-Báez et al.,
2013), leading to the hypothesis that PP2A may regulate ARF6-
dependent trafficking. Here, we show that the ‘tumor suppressor
lipid’ ceramide and the anti-neoplastic sphingolipid-like small
molecules FTY720 and 893 decrease cell surface nutrient
transporter levels in mammalian cells by reducing ARF6-GTP
levels, dissolving the tubular recycling endosome and disrupting
endocytic recycling.
RESULTS
Natural and synthetic sphingolipids trap cell surface nutrient
transporters in a recycling compartment
CD98 (4F2hc, SLC3A2) is a chaperone protein for LAT1 (SLC7A5)
and xCT (SLC7A11), two amino acid transporter proteins whose
overexpression in cancer cells is correlated with poor prognosis
(Selwan et al., 2016). FTY720 downregulates CD98 and LAT1 in
mammalian cells (Barthelemy et al., 2017; Kim et al., 2016; Romero
Rosales et al., 2011). Surface levels of CD98 are readily quantified
using flow cytometry while antibodies recognizing the exofacial
domains of other nutrient transporters are not generally available,
most likely because glycosylation of the extracellular regions
of these proteins sterically hinders antibody binding. As expected,
the sphingolipids ceramide, sphingosine, FTY720 and 893
downregulated CD98 in mammalian cells (Guenther et al., 2008;
Kim et al., 2016; Perryman et al., 2016; Romero Rosales et al., 2011;
Fig. 1A,B and Fig. S1). Importantly, bacterial sphingomyelinase, an
enzyme that converts plasma membrane sphingomyelin into
physiological long-chain ceramides, also reduces cell surface
levels of transporters, indicating that natural ceramides, not just
more-soluble short-chain analogs, share this activity (Guenther
et al., 2008; Fig. 1A,B). As small molecule and protein inhibitors
of PP2A block transporter loss (Guenther et al., 2008; Kim et al.,
2016; Romero Rosales et al., 2011), this phenotype is not due to
the direct effects of sphingolipids on membranes (Trajkovic et al.,
2008).
To begin to dissect the mechanism underlying sphingolipid-
induced nutrient transporter loss in mammalian cells, a kinetic study
of transporter colocalization with markers for different endocytic
compartments was performed. In sphingolipid-treated cells,
internalized CD98 did not colocalize with the early endosome
marker EEA1 at any time point (Fig. 1C and Fig. S2A,B).
Sphingolipids induced colocalization of intracellular CD98 and the
trans-Golgi network marker TGN46; however, TGN46 localization
was itself altered by sphingolipids (Fig. 1D, Fig. S2C,D and
Fig. S3A,B). In control cells, TGN46 was mostly colocalized with
GM130 as expected (Fig. S3A). In FTY720-treated cells, some
TGN46 still colocalized with GM130, but most TGN46 molecules
were redistributed to peripheral, vesicular structures. GM130
localization was not altered, suggesting that the cis-Golgi
remained intact. While the steady state localization pattern of
TGN46 is predominantly in the trans-Golgi network, TGN46
traffics between the trans-Golgi network and the plasma membrane
along tubular endosome intermediates (Ghosh et al., 1998;
Maxfield and McGraw, 2004; Prescott et al., 1997). The
peripheral punctate distribution of both TGN46 and CD98 in
sphingolipid-treated cells (Fig. 1D and Fig. S2C,D) suggested that
both were trapped in a recycling intermediate. Consistent with this
hypothesis, a subset of internalized transferrin receptor (TfR)
colocalized with GLUT1 in sphingolipid-treated cells, most likely
in recycling endosomes that receive cargo from both the clathrin-
independent endocytosis (CIE) and clathrin-mediated endocytosis
(CME) pathways (Fig. 1E and Fig. S4A,B). Sphingolipids also
increased co-localization of TGN46 and TfR, again suggesting that
recycling pathways are disrupted (Fig. S3B). CD98 partially
colocalized with the late endosome/lysosome marker LAMP1
only at late time points (Fig. 1F, Fig. S4C,D) suggesting that nutrient
transporters that fail to recycle may eventually be rerouted towards
the degradative pathway. In ceramide-treated cells, CD98 was
present in the interior of the LAMP1-positive endosomes,
suggesting it was present in the limiting membrane of
intraluminal vesicles that have budded into the multivesicular
body (MVB) prior to lysosomal degradation (Fig. 1F). In 893-
treated cells where intraluminal budding is disrupted due to the
mislocalization of the lipid kinase PIKfyve and the loss of PI(3,5)P2
from MVB membranes (Kim et al., 2016), CD98 remained
associated with the limiting membranes of LAMP1-positive
endosomes (Fig. 1F). Taken together, these colocalization studies
suggest that natural and synthetic sphingolipids trap endocytosed
nutrient transporters in recycling endosomes, but these proteins are
eventually sent to the lysosome for degradation when they fail
to recycle.
As mentioned above, small-molecule inhibitors of PP2A rescue
cells from the trafficking defects induced by sphingolipids,
indicating PP2A activation is necessary to produce these
phenotypes. Consistent with this model, dihydroceramide, which
differs from ceramide by a single unsaturated bond (Fig. S1) and
does not activate PP2A (Chalfant et al., 2004; Dobrowsky et al.,
1993; Kowluru and Metz, 1997) also did not alter the localization
of CD98, TGN46, GLUT1 or the TfR (Fig. S5A,B). An 893
analog, 893-lactam, that lacks a charge on the pyrrolidine nitrogen
fails to downregulate nutrient transporter proteins or induce
vacuolation, which are both PP2A-dependent phenotypes
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(Fig. S1; Chen et al., 2016; Perryman et al., 2016). Also,
893-lactam did not affect the localization of these recycling
proteins (Fig. S5A,B). In summary, a subset of sphingolipids
that activate PP2A trap several proteins in what appears to be a
recycling compartment.
Sphingolipids increase internalization and block endosomal
recycling of nutrient transporters downstream of PP2A
activation
The downregulation of nutrient transporter proteins in sphingolipid-
treated cells could result from an increased rate of endocytosis, a
Fig. 1. Natural and synthetic sphingolipids trap plasma membrane nutrient transporters along with recycling cargo. (A) FL5.12 cells were treated with
vehicle, C2-ceramide (50 µM), bacterial sphingomyelinase (bSMase; 100 mU/ml), FTY720 (5 µM) or SH-BC-893 (893, 5 µM) for 3 h then stained for surface
CD98. (B) HeLa cells were treated as in A for 12 h then stained for CD98. All images were collected with the same microscope and processed using the same
settings. (C-F) HeLa cells were treated with vehicle, C2-ceramide (50 µM), or 893 (10 µM) for 12 h, then stained for CD98 and EEA1 (C), CD98 and TGN46 (D),
GLUT1 and transferrin receptor (TfR) (E), or CD98 and LAMP1 (F). n≥3 for all panels. Data in A aremeans±s.e.m. One-way ANOVAwas used to compare treated
samples with control, ***P≤0.001. Dunnett’s test was used to correct for multiple comparisons. Scale bars: 10 µm. See also Figs S1-S5.
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decreased rate of endosomal recycling or a combination of the
two. Internalization of cell surface transporters in response to
sphingolipids was quantified using a flow cytometry-based assay.
Briefly, live cells were incubated with unlabeled primary antibody
on ice, washed and then shifted to 37°C in the presence or absence
of FTY720 for various intervals before staining with fluorochrome-
conjugated secondary antibodies on ice. Using this approach,
downregulation of molecules that were initially present on the cell
surface can be selectively measured. Cell lines that grow in
suspension were used for these assays to minimize artifacts that
might result from loss of adhesion-dependent signal transduction
after trypsinization and to simplify the experimental design. Over
the course of the experiment, minimal CD98 was lost from the
surface of murine FL5.12 hematopoietic cells in the absence of
exogenous sphingolipids, confirming that antibody binding does
not itself trigger CD98 endocytosis (Fig. 2A). Internalization of cell
surface CD98 was dramatically enhanced by FTY720 with only
48% of the CD98 molecules that were initially on the surface
remaining after 30 min of exposure. Similar results were obtained in
human SupB15 leukemia cells. In contrast, FTY720 did not increase
transferrin (Tf) internalization in either FL5.12 or SupB15
cells, suggesting that CME is not stimulated by sphingolipids
(Fig. 2B). These results suggest that sphingolipids selectively
increase the internalization of plasma membrane-localized CD98
but not the TfR.
Endocytic recycling also controls the surface level of plasma
membrane proteins. The results in Fig. 2A could have been obtained
if CD98 has a high basal internalization rate that was not affected by
FTY720 and this sphingolipid selectively blocks recycling. To
evaluate whether sphingolipids impede endosomal recycling, a
Fig. 2. Sphingolipids inhibit recycling
of nutrient transporters in a PP2A-
dependent manner. (A) Loss of surface
CD98 in FL5.12 and SupB15 cells.
Cells were incubated with a primary
unconjugated CD98 antibody on ice for
30 min. Cells were then treated with
vehicle or FTY720 at 37°C for the
indicated times, incubated on ice with
secondary antibody for 30 min, and
surface CD98 measured by flow
cytometry. (B) Transferrin uptake in
FL5.12 and SupB15 cells with or without
FTY720. (C) CD98 recycling in SupB15
cells. Cells were incubated with primary
CD98 antibody as in A, then treated with
vehicle or FTY720 for 1 h at which point
cells were washed and returned to
vehicle- or FTY720-containing medium
for 30 min. Surface CD98 levels were
then measured by flow cytometry.
(D) Tf recycling assay conducted in the
presence or absence of FTY720.
(E) FL5.12 cells pre-treated (1.5 h) with
PP1 inhibitor tautomycin (TT, 200 nM) or
PP2A inhibitors cantharidin (CT, 10 μM)
or calyculin A (calA, 5 nM) were treated
with FTY720 for 1 h and surface
CD98 quantified by flow cytometry.
(F) Internalization of surface CD98 was
measured as in A, cells were pre-treated
with calyculin A (5 nM) for 1 h where
indicated. (G) Following surface labeling
with a primary antibody, FL5.12 cells
were treated with FTY720 for 1 h at which
point vehicle or calyculin A (10 nM) was
added for an additional 1 h. Cells were
then stained with secondary antibody
and surface CD98 measured using flow
cytometry. FTY720 was used at 5 μM.
Means±s.e.m. are shown; n≥3 in all
panels. Two-tailed t-test was used to
compare sphingolipid-treated time points
with vehicle time points. n.s., not
significant; *P≤0.05; ***P≤0.001.
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modified version of this flow cytometry assay was utilized. In these
recycling studies, surface CD98 was again selectively labeled with
primary antibodies, but cells were washed and transferred to
FTY720-free medium at 1 h, a time point after CD98 loss had
plateaued. As expected, the initial treatment with FTY720 triggered
the internalization of about 35% of the cell-surface CD98 in
SupB15 cells (Fig. 2A,C). However, washing out FTY720 after 1 h
led to the complete restoration of internalized CD98 to the cell
surface within 30 min (Fig. 2C). In control samples where FTY720
was replenished after washing, internalized CD98 did not return to
the surface. Consistent with the colocalization studies presented in
Fig. 1D,E, these results suggest that sphingolipids trap CD98 in a
recycling compartment. As TfR was trapped intracellularly along
with GLUT1 and TGN46 in sphingolipid-treated cells (Fig. 1E,
Fig. S3B and Fig. S4A,B), Tf recycling was also evaluated.
Internalized Tf was recycled more slowly in FTY720-treated cells
(Fig. 2D). As TfR internalization was not altered by FTY720
(Fig. 2B), sphingolipids may increase the internalization of a subset
of clathrin-independent cargo while having a more global negative
impact on endocytic recycling.
Sphingolipid-induced nutrient transporter downregulation
requires PP2A activation (Guenther et al., 2008; Kim et al., 2016;
Romero Rosales et al., 2011). As expected, the PP2A inhibitors
calyculin A and cantharidin blocked FTY720-induced nutrient
transporter loss (Fig. 2E). Calyculin A and cantharidin inhibit PP1
at ∼2-fold and ∼10-fold higher concentrations, respectively, than
they inhibit PP2A (Swingle et al., 2007). However, the PP1-specific
inhibitor tautomycin did not block CD98 loss in response to
FTY720 (Fig. 2E). In an internalization assay selectively
monitoring cell surface CD98, PP2A inhibition with calyculin A
maintained plasma membrane-localized CD98 at initial levels
(Fig. 2F). Moreover, the CD98 recycling defect could be attributed
to PP2A activation. In recycling assays where cell surface CD98
was labeled and then 1 h was allowed for internalization, calyculin
A resulted in the return of internalized CD98 to the cell surface even
in the continued presence of FTY720 (Fig. 2G). Taken together,
these experiments suggest that PP2A activation by sphingolipids
blocks endocytic recycling.
Sphingolipids disrupt the tubular recycling endosome that
receives CIE cargo
Several of the nutrient transporter proteins affected by sphingolipids,
including CD98, LAT1, GLUT1 and MCT1, are ARF6 cargo
proteins that are internalized by CIE and recycled back to the plasma
membrane via the tubular recycling endosome (TRE) (Eyster et al.,
2009; Maldonado-Báez et al., 2013). The recycling of such cargo
from the TRE depends on ARF6-GTP; expressing the dominant-
negative ARF6 mutant T27N or knocking down the ARF6 GEF
cytohesin-3 (GRP1) ablates endosomal recycling from the TRE
(D’Souza-Schorey et al., 1998; Eyster et al., 2009; Li et al., 2012;
Maldonado-Báez et al., 2013; Rahajeng et al., 2012; Schweitzer
et al., 2011; Zimmermann et al., 2005). The molecular scaffold
MICAL-L1 recruits ARF6 to the TRE alongwith additional proteins
involved in membrane tubulation and scission (Cai et al., 2014;
Giridharan et al., 2013; Rahajeng et al., 2012; Sharma et al., 2009).
Given that the proteins downregulated by sphingolipids are ARF6
cargo that move through the TRE during recycling, we evaluated the
effect of sphingolipids on the morphology of this recycling
compartment by monitoring MICAL-L1 localization.
HeLa cells are commonly used to study TRE function (Cai
et al., 2014; Giridharan et al., 2012, 2013; Rahajeng et al., 2012;
Reinecke et al., 2015; Sharma et al., 2009). An extensive TRE is
also present in COS7, COS1, MCF7, dendritic cells and intestinal
cells of Caenorhabditis elegans (Chen et al., 2014; Grant and
Donaldson, 2009; Montesinos et al., 2005; Vidal-Quadras et al.,
2011; Walseng et al., 2008; Zimmermann et al., 2005); less
elaborate forms of an ARF6-regulated tubular recycling
compartment are likely to exist in all mammalian cells.
Consistent with the effect of sphingolipids on CD98
internalization and recycling (Fig. 2), both FTY720 and 893
triggered a dramatic relocalization of CD98 to tubular structures
within 30 min in HeLa cells (Fig. 3A and not shown). Additional
CIE cargo proteins that are downregulated by sphingolipids,
GLUT1 and MCT1, also accumulated in tubules in response to
FTY720 or 893 (data not shown). To confirm that these tubules
represented the TRE, cells were stained for both CD98 and
MICAL-L1. Because the antibodies against CD98 and MICAL-L1
were both generated in mice, GFP-tagged MICAL-L1 was
expressed to facilitate colocalization studies. As expected,
tubules containing CD98 were also positive for MICAL-L1
(Fig. 3B). Moreover, consistent with this structure receiving an
enhanced endocytic load, the MICAL-L1-positive TRE expanded
upon exposure to 893 (Fig. 3C,D). Following this initial
expansion, tubular MICAL-L1 staining was completely lost,
shifting to a diffuse, cytoplasmic pattern after 3 h with no
decrease in total cellular MICAL-L1 (Fig. 3C-E). Similarly to
MICAL-L1, CD98 lost its tubular distribution at 3 h (Fig. 3A) and
no longer colocalized with MICAL-L1 at 6 h (Fig. 3F). MICAL-
L1 is essential for proper TRE function as it recruits many proteins
required for recycling, including ARF6, RAB35, syndapin2,
RAB8, RAB10, and EHD1 (Giridharan et al., 2012, 2013;
Rahajeng et al., 2012; Sharma et al., 2009). Loss of the
molecular scaffold MICAL-L1 suggests that proteins critical for
endocytic recycling from the TRE would not be recruited. Indeed,
tubular ARF6 and RAB35 staining, and colocalization with
MICAL-L1 was eliminated after 6 h of exposure to ceramide or
893 (Fig. S6A,B). These results suggest that the failure to retain
MICAL-L1 on the TRE contributes to the disruption in endocytic
recycling in sphingolipid-treated cells.
In marked contrast to results obtained with FTY720 and 893
(Fig. 3A-C), ceramide did not induce a tubular MICAL-L1 or CD98
staining pattern at early time points (Fig. 4A,B). While tubular
MICAL-L1 persisted until 3 h in cells treated with FTY720 or 893
(Fig. 3C,D), tubular MICAL-L1 localization was lost within 30 min
of ceramide addition (Fig. S6A,B). Loss of tubular MICAL-L1
staining in ceramide-exposed cells was not due to degradation as
MICAL-L1 total protein levels were not reduced (Fig. 3E). As
FTY720, 893 and ceramide induce nutrient transporter loss with
similar kinetics and to a similar extent (Fig. 1A-F; Guenther et al.,
2008; Kim et al., 2016; Romero Rosales et al., 2011), this
discrepancy in their effects on the TRE was unexpected.
However, FTY720 and 893 have effects on intracellular
trafficking that are not shared with ceramide (Kim et al., 2016).
FTY720 and 893 induce profound cytoplasmic vacuolation by
mislocalizing the phosphatidyl inositol kinase PIKfyve and its
product PI(3,5)P2 to an abnormal compartment, inhibiting
activation of the effector protein TRPML1 and the release of Ca2+
necessary for lysosomal fusion. Ceramide, in contrast, does not alter
PIKfyve localization or inhibit lysosomal fusion reactions. To
assess whether the loss of PI(3,5)P2 from the MVB could account
for the disparate effects of ceramide and FTY720/893 on MICAL-
L1 localization (Fig. 4A), MICAL-L1 localization was evaluated in
cells treated with the PIKfyve kinase inhibitor YM201636 alone or
in combination with ceramide. Intriguingly, MICAL-L1-positive
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tubules were longer and more numerous in cells treated with
YM201636, a phenotype similar to that seen with FTY720 and 893
at early time points (Fig. 3C,D, Fig. 4A,C and Fig. S6A,B).
Whereas about half of the cells normally contain a well-elaborated
TRE, nearly 100% of the cells treated with FTY720, 893 or
YM201636 contain a TRE structure with extended tubules (Fig. 4A,
C,D and Fig. S6A,B). YM201636 did not prevent ceramide-induced
dispersion of MICAL-L1, suggesting that FTY720 and 893 may
trigger additional trafficking disruptions that affect TRE
morphology (Fig. 4D). As YM201636 does not reduce surface
nutrient transporter levels as a single agent and does not increase the
transporter loss induced by ceramide (Fig. 4C and Kim et al., 2016),
it seems unlikely that hypertubulation interferes with recycling or
contributes to transporter loss. Rather, the dispersion of MICAL-L1
that is triggered by ceramide immediately or by FTY720 and
893 after 3 h is more likely to be associated with a transporter
recycling defect.
Endogenous and synthetic sphingolipids that downregulate
nutrient transporters inactivate the ARF6 GTPase
ARF6 activation is required for recycling of a number of cargo
proteins that localize to the TRE (D’Souza-Schorey et al., 1998;
Donaldson, 2003; Maldonado-Báez et al., 2013). ARF6 is also
necessary to maintain the TRE (Rahajeng et al., 2012). Thus, the
observed effects of sphingolipids on endocytic recycling and the
TRE suggest that sphingolipids might inactivate ARF6. To test this
model, ARF6-GTP levels were measured using a published ARF6
effector pull-down assay (Cohen and Donaldson, 2010). The ARF6
inhibitor SecinH3 inactivates the cytohesin family of ARF6 GEFs
and reduced ARF6-GTP to about 60% of basal levels; C2-ceramide,
bSMase, FTY720 and 893 decreased ARF6-GTP levels to a
similar degree in a dose-responsive and time-dependent manner
(Fig. 5A-C). FTY720 inactivated ARF6 in multiple cell types
including MDA-MB-231 (human breast cancer), HeLa (human
cervical carcinoma), SW620 (human colorectal cancer), PC3
Fig. 3. Sphingolipids send nutrient
transporters to the tubular recycling
endosome prior to its dissolution. (A) HeLa
cells treated with 893 (10 µM) for 0.5, 1, 3 or 6 h
were stained for CD98. (B) HeLa cells expressing
GFP-MICAL-L1 were treated with 893 (10 µM) for
1 h and stained for CD98. (C) HeLa cells treated as
in A but stained for MICAL-L1. (D) Percentage
of cells that exhibit tubular MICAL-L1 staining.
Means±s.e.m. shown of n≥3. An ordinary one-way
ANOVA was used to compare with time zero,
***P≤0.001. Dunnett’s test was used to correct for
multiple comparisons. (E) Representative blot for
HeLa cells treated with FTY720 (10 µM), 893
(10 µM), C2-ceramide (50 µM) for 6 h, lysed,
and blotted for MICAL-L1 and tubulin. (F) HeLa
cells expressing GFP-MICAL-L1 treated with
893 (10 µM) for 6 h and stained for CD98.
Scale bars: 10 µm.
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(human prostate cancer) and SupB15 (human acute lymphoblastic
leukemia) cells (Fig. 5D). Sphingolipids induce nutrient transporter
loss in all of these cell types (Guenther et al., 2008; Kim et al., 2016;
Romero Rosales et al., 2011). Moreover, sphingolipids that do not
downregulate CD98 failed to inactivate ARF6. C2-dihydroceramide
did not trigger CD98 downregulation, TGN46 mislocalization,
GLUT1 and TfR colocalization, or dissolution of MICAL-L1-
positive TRE (Fig. 5E and Fig. S5A-C). C2-dihydroceramide also
failed to kill cells (Fig. 5F). Consistent with the expectation that loss
of MICAL-L1 on the TRE and mislocalization of recycling cargo
TGN46 and TfR is due to ARF6 inactivation, dihydroceramide
failed to reduce ARF6-GTP levels (Fig. 5G). Similar results were
obtained with the inactive analog 893-lactam (Fig. S5A-D). As C2-
dihydroceramide also fails to activate PP2A in vitro (Chalfant et al.,
2004; Kim et al., 2016), these results are consistent with placement
of ARF6 inactivation downstream of PP2A activation. Also
consistent with this model, a structurally unrelated small-molecule
activator of PP2A, perphenazine (PPZ), was sufficient to trigger
mislocalization of CD98 and TGN46 and to eliminate tubular
MICAL-L1 staining (Fig. S7A,B). As YM201636 did not alter
ARF6-GTP levels or disrupt ARF6 recruitment to the TRE
(Fig. S7C-D), ARF6 inactivation is unlikely to lie downstream of
PIKfyve mislocalization by FTY720 or 893. Together, these data
support the model that PP2A activation leads to ARF6 inactivation
and a block in endocytic recycling.
If PP2A activation is upstream of ARF6 inactivation, then
inhibition of PP2A should maintain ARF6-GTP levels in
sphingolipid-treated cells. Unexpectedly, the PP2A inhibitor
calyculin A that blocked transporter internalization and restored
endocytic recycling (Fig. 2E-G) inactivated ARF6 even in the
absence of exogenous sphingolipids (Fig. 5H). This result may
reflect the fact that PP2A is a heterotrimeric enzyme that can take
over 50 different forms with distinct subunit composition and
substrate preferences (Sangodkar et al., 2016). Sphingolipids may
activate only a subset of PP2A isoforms, but calyculin A inhibits all
PP2A heterotrimers, including sphingolipid-insensitive PP2A
heterotrimers that might promote ARF6 activation. Off-target
effects on proteins other than PP2A may also contribute to the
inactivation of ARF6 by calyculin A. Our efforts to measure ARF6-
GTP levels in cells where PP2A was genetically inhibited were
unsuccessful. Loss of PP2A catalytic activity is cell lethal, and
sufficient quantities of viable cells with PP2A-A or PP2A-C subunit
knockdown could not be generated for use in effector pulldown
assays. Knocking down individual PP2A-B subunits was a less-
toxic approach, but failed to protect cells from transporter loss (data
not shown). While SV40 small t antigen blocked sphingolipid-
induced nutrient transporter loss in transient transfection assays
(Kim et al., 2016), expression levels achieved in stable populations
or cell clones were not sufficient to protect against transporter
loss; similar results were obtained in cells stably overexpressing
the PP2A inhibitor I2PP2A/SET (data not shown). Given these
technical difficulties, a definitive test of whether ARF6 inactivation
lies downstream of sphingolipid-induced PP2A activation will
require additional mechanistic insight. Nonetheless, the correlation
between the ability of sphingolipids to trigger nutrient transporter
loss, starve cells, reduce ARF6-GTP levels and activate PP2A
suggests that PP2A activation is likely to be upstream of ARF6
inactivation.
ARF6 inactivation is necessary and sufficient to account for
reduced nutrient transporter recycling in sphingolipid-
treated cells
Dominant-negative and constitutively active mutants are routinely
used to study GTPase function. Constitutively active mutants exist
preferentially in the GTP-bound state due to mutations that
prevent GTP hydrolysis, whereas dominant-negative mutants are
Fig. 4. Hyper-tubulation of the TRE
occurs downstream of PIKfyve
inhibition. (A) HeLa cells treated with
vehicle, FTY720 (10 µM), 893 (10 µM)
or C2-ceramide (50 µM) for 1 h or 6 h
were stained for MICAL-L1. (B) HeLa
cells treated with vehicle, FTY720
(10 µM), 893 (10 µM) or C2-ceramide
(50 µM) for 1 h and stained for CD98.
(C) HeLa cells treated with PIKfyve
inhibitor YM201636 (800 nM) for 1 h
and stained for MICAL-L1 or CD98.
(D) HeLa cells treated with
C2-ceramide (50 µM) or YM201636
(800 nM) alone or in combination for
1 h were stained for MICAL-L1. Scale
bars: 10 µm.
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preferentially in the GDP-bound state and compete with the
endogenous GTPase for GEFs. While these mutants can provide
key insights, GTPase cycling between the GDP- and GTP-bound
forms is required for normal GTPase function. Indeed, the
constitutively active ARF6 mutant ARF6-Q67L causes nutrient
transporter proteins to accumulate intracellularly in large,
perinuclear vesicles and, not surprisingly, failed to restore nutrient
transporters to the surface in sphingolipid-treated cells (Eyster et al.,
2009 and not shown). However, consistent with our finding that
sphingolipids inactivate ARF6, the dominant-negative mutant
ARF6-T27N drove CD98 into tubular endosomes and cytoplasmic
puncta similar to the phenotype in sphingolipid-treated cells
(Fig. 3A, Fig. 4B and Fig. 6A,B). ARF6-T27N also mislocalized
the recycling cargo TGN46 to peripheral vesicular structures,
suggesting that ARF6 inactivation was sufficient to explain the
recycling defects observed with sphingolipids (Fig. S7E). Both
the cytohesin inhibitor SecinH3 and the allosteric ARF6
inhibitor NAV2729 also disrupted the localization pattern of
CD98 (Fig. 6C,D) and TGN46 (Fig. S7F) and phenocopied the
effects of sphingolipids on MICAL-L1, eliminating tubular
MICAL-L1 localization (Fig. 6F) and blocking ARF6 and RAB35
recruitment to the TRE in a similar manner to 893 and ceramide
(Fig. S6A-C). If ARF6 activity is necessary for nutrient transporter
recycling from the TRE, then reducing ARF6-GTP with SecinH3
should recapitulate the recycling block induced by sphingolipids. To
measure recycling, HeLa cells were treated with ceramide or 893 to
induce CD98 and GLUT1 internalization and cytoplasmic levels of
transporters were compared with levels in untreated control cells
(Fig. 6G). Washing out sphingolipids after 1 h reduced the amount
of intracellular transporter analogous to results obtained in SupB15
leukemia cells (Fig. 2C and Fig. 6G). Inclusion of SecinH3 in the
medium after 893 or ceramide washout was sufficient to retain both
CD98 andGLUT1 in swollen endosomal structures (Fig. 6G). Taken
together, genetic and small-molecule inhibitor studies indicate
that reducing ARF6-GTP levels is sufficient to account for the
sphingolipid-induced defect in nutrient transporter recycling.
Fig. 5. Endogenous and synthetic sphingolipids that downregulate nutrient transporters also inactivate the ARF6 GTPase. (A) ARF6-GTP levels
normalized to total ARF6 in FL5.12 cells treated with the cytohesin inhibitor SecinH3 (30 µM), C2-ceramide (50 µM), bacterial sphingomyelinase (bSMase;
100 mU/ml), FTY720 (5 µM) or 893 (5 µM) for 3 h. (B,C) ARF6-GTP levels in FL5.12 cells treated with FTY720 (0, 1.25, 2.5, 5 or 10 µM) for 30 min (B) or with
10 µM FTY720 for 5, 15 or 30 min (C). (D) ARF6-GTP levels in FL5.12, MDA-MB-231, HeLa, SW620, PC3 or SupB15 treated for 3 h with FTY720 (10 µM).
(E) Steady state surface CD98 levels in FL5.12 cells treated with C2-ceramide or C2-dihydroceramide at the indicated concentrations for 3 h. (F) Viability of
C2-ceramide- or C2-dihydroceramide-treated FL5.12 cells at 48 h. (G) ARF6-GTP levels in FL5.12 cells treated with C2-ceramide (50 µM) or C2-dihydroceramide
(50 µM). (H) ARF6-GTP levels in FL5.12 cells treated with CalyculinA (10 nM) for 1 h. Means±s.e.m. shown of n≥3 in all panels. Using two-tailed t-test (D-F,H) or
ordinary one-way ANOVA (A-C,G): n.s., not significant; *P≤0.05; **P≤0.01; ***P≤0.001. Dunnett’s test was used to correct for multiple comparisons (A-C,G). See
also Fig. S5.
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To determine whether ARF6 inactivation was necessary for
sphingolipid-induced nutrient transporter loss, we attempted to
maintain ARF6-GTP in sphingolipid-treated cells. As mentioned
above, the ARF6 GTPase cycle is critical for its normal function and
the constitutively active ARF6-Q67L mutant disrupts rather than
facilitates ARF6-dependent recycling (Cohen et al., 2007; D’Souza-
Schorey et al., 1998; Donaldson, 2003; Donaldson et al., 2009;
Eyster et al., 2009; Maldonado-Báez et al., 2013; Santy, 2002).
Overexpression of ARF6 GEFs is commonly employed as a more
physiological means to activate ARF6 (Cohen and Donaldson,
2010; Kanamarlapudi, 2014; Santy and Casanova, 2001). However,
GEF overexpression can also lead to ARF6 hyperactivation,
inducing abnormal, non-physiological phenotypes similarly to the
ARF6-Q67L mutant (Cohen et al., 2007; Li et al., 2012; Monier
et al., 1998). The PH domain of SLM proteins bears significant
homology to the PH domain of cytohesin family GEFs, the
cytohesin inhibitor SecinH3 recapitulated many of the effects of
sphingolipids on endocytic trafficking (Fig. 6C-G),and cytohesin-3
(GRP1) promotes GLUT4 recycling in response to insulin (Li et al.,
2012). Thus, we attempted to maintain ARF6-GTP levels in
sphingolipid-treated cells by overexpressing GRP1. GRP1 is
activated by insulin-dependent AKT-mediated phosphorylation of
Ser155 and Thr280 (Li et al., 2012). Because we suspected
that PP2A activation was upstream of ARF6 inactivation, a
constitutively active, phosphomimetic mutant where these serine
and threonine residues were converted to aspartic acid (GRP1-DD)
was also evaluated. HeLa cells were transfected with GFP (negative
control), wild-type GRP1, or GRP1-DD and CD98 localization
with or without 893 was monitored by immunofluorescence
microscopy. As expected, 893 downregulated CD98 in GFP-
expressing cells leading to its accumulation in swollen endocytic
structures (Fig. 7A). Overexpression of wild-type GRP1 led to an
unexpected phenotype: CD98 was no longer evenly distributed
along the plasma membrane but rather collected in membrane
Fig. 6. ARF6 inactivation is sufficient to inhibit nutrient transporter recycling. (A) HeLa cells expressing HA-ARF6 or HA-ARF6-T27N stained for CD98.
(B) Quantification of intracellular CD98 intensity in A. (C) Surface CD98 quantification and ARF6-GTP levels in FL5.12 cells treated with FTY720 (5 µM) or
SecinH3 (30 µM) for 3 h. (D) HeLa cells treated with SecinH3 (30 µM) or NAV2729 (12.5 µM) for 16 h and stained for CD98. (E) HeLa cells treated with SecinH3
(30 µM) or NAV2729 (12.5 µM) for 1 or 6 h and stained for MICAL-L1. (F) Quantification of E. (G) Cytoplasmic intensity quantification of CD98 and GLUT1
in HeLa cells treated with vehicle, 893 (10 µM), or C2-ceramide (50 µM) for 1 h, washed with PBS, then returned to 893 (10 µM) or placed in vehicle or SecinH3
(30 µM) for 2 h. Means±s.e.m. shown for n≥3 in all panels. Using a two-tailed t-test (B) or an ordinary one-way ANOVA (C,F,G) to compare treated samples
with controls: n.s., not significant; *P≤0.05; **P≤0.01; ***P≤0.001. Dunnett’s test was used in C,F and Tukey’s test was used in G to correct for multiple
comparisons. Scale bars: 10 µm. See also Figs S6 and S7.
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ruffles and in small endosomes that accumulated in the perinuclear
region. While CD98 localization to plasma membrane ruffles was
not observed in cells expressing the activated mutant ARF6-Q67L,
accumulation of CD98 in perinuclear vesicles is consistent with
ARF6 hyperactivation (data not shown and Eyster et al., 2009).
Given its basal effects on CD98 localization, it was not surprising
that overexpression of wild-type GRP1 failed to protect from
sphingolipid-induced nutrient transporter loss (Fig. 7A).
Intriguingly, CD98 localization was not basally altered in GRP1-
DD-expressing cells despite the reported constitutive activity of this
mutant (Fig. 7A and Li et al., 2012); sequencing of the plasmids
used in this experiment confirmed the identity of the wild-type and
mutant constructs. The increased localization of GRP1-DD to
endosomes might contribute to its differential activity (Li et al.,
2012). Importantly, GRP1-DD eliminated the endosomal CD98
signal in 893-treated cells (Fig. 7A), suggesting that GRP1-DD
might maintain recycling in sphingolipid-treated cells. Given that
ARF6 inhibition destabilizes the TRE and GRP1-DD restores
recycling, this mutant might also stabilize the TRE in 893-treated
cells. Indeed, while MICAL-L1-positive tubules were absent in
GFP- and GRP1-expressing cells exposed to 893, MICAL-L1
tubules were readily detectable in GRP1-DD-expressing cells
exposed to 893 (Fig. 7B). Disappointingly, populations or clones
stably expressing GRP1-DD had markedly lower expression levels
of exogenous GRP1 compared with the transient overexpressing
cells and were not protected from CD98 loss (data not shown). As a
result, the ability of GRP1-DD to rescue cells from 893-induced
ARF6 inactivation and cell death could not be evaluated. Moreover,
changes in GRP1 phosphorylation in response to sphingolipids
could not be detected using an antibody that recognizes
phosphorylated AKT substrates (Li et al., 2012) (data not shown).
In summary, these studies suggest that sphingolipids disrupt
endocytic recycling by activating PP2A and inactivating
ARF6 (Fig. 7C).
ARF6 inhibition contributes to the anti-neoplastic effects of
synthetic sphingolipids
Sphingolipids selectively kill cancer cells, in part, by starving them
secondary to nutrient transporter downregulation (Guenther et al.,
2008; Kim et al., 2016; Romero Rosales et al., 2011). If ARF6
inactivation blocks access to nutrients by limiting nutrient
transporter recycling, then small molecules that inactivate ARF6
may sensitize cancer cells to suboptimal non-cytotoxic
concentrations of anti-neoplastic sphingolipids. In SupB15
leukemia cells, SecinH3 was not cytotoxic or even cytostatic as a
single agent (Fig. 8A and not shown). At 5 µM, FTY720 blocked
Fig. 7. A phosphomimetic mutant of GRP1 protects nutrient transporter recycling from inhibition by 893. (A) HeLa cells expressing GFP alone, myc-
tagged wild-type GRP1, or myc-tagged GRP1 S155D+T280D (GRP1-DD) were treated with 893 (5 µM) for 6 h and stained for GFP or myc tag and CD98. (B) As
in A, except cells were stained for MICAL-L1 and myc tag or GFP. Scale bars: 10 µm. (C) Model for regulation of endocytic recycling by sphingolipids.
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SupB15 cell proliferation but did not induce cell death. However,
the combination of 5 µM FTY720 with a dose of SecinH3 that
inactivates ARF6 (Fig. 5A) killed >60% of the leukemia cells in
72 h (Fig. 8A). As a single agent, SecinH3 did not affect the
proliferation or viability of SW620 colorectal cancer cells, PC3
prostate cancer cells, MDA-MB-231 breast cancer cells or MCF7
breast cancer cells (Fig. 8B-E and data not shown). However, in
each of these cell lines, SecinH3 dramatically potentiated the effect
of a suboptimal concentration of 893 suggesting that ARF6
inactivation contributes to sphingolipid-induced cell death.
Similar results were obtained with the allosteric ARF6 inhibitor
NAV2729 inMDA-MB-231 cells (Fig. 8F). In vitro, cancer cells are
at least 10-fold more sensitive than non-transformed cells to the
cytotoxic effects of 893, most likely because their oncogenic
mutations drive anabolism and limit their ability to make adaptive
metabolic changes that would compensate for reduced nutrient
access (Kim et al., 2016). To test whether combining SecinH3 with
893 would reduce or expand this therapeutic index, colony
formation by peripheral blood mononuclear cells was measured in
the presence or absence of SecinH3 and 893. In contrast to our
results in five different human cancer cell lines (Fig. 8A-E),
SecinH3 did not sensitize PBMCs to 893 (Fig. 8G). In fact, SecinH3
may have partially protected normal cells from 893 although this
effect was not statistically significant. These studies suggest that
ARF6 inactivation contributes to the anti-neoplastic activity of
sphingolipids and that combining ARF6 inhibitors with 893 could
extend the dose range over which 893 is effective without increasing
toxicity to normal proliferating cells.
DISCUSSION
While we and others have previously shown that a subset of
sphingolipids downregulate glucose and amino acid transporters
(Barthelemy et al., 2017; Bultynck et al., 2006; Chung et al., 2001;
Guenther et al., 2008; Kim et al., 2016; Romero Rosales et al., 2011;
Skrzypek et al., 1998; Summers et al., 1998), the molecular
mechanism is incompletely defined. As restricting nutrient access is
a key mode of action for both endogenous and synthetic anti-
neoplastic sphingolipids, understanding the molecular mechanism
underlying this phenotype will provide insight into normal cell
biology and clarify which tumor cells will be sensitive and resistant to
therapeutic approaches that involve sphingolipid delivery or
generation. Studies in yeast suggest that both internalization and
recycling of nutrient transporter proteins are affected by sphingolipids
(Barthelemy et al., 2017; Bultynck et al., 2006; Chung et al., 2001;
Kamble et al., 2011; Welsch et al., 2004). The work presented here
demonstrates that sphingolipids block transporter recycling in
mammalian cells. While the molecular details of sphingolipid-
induced nutrient transporter loss differ between yeast andmammalian
cells, there are several interesting parallels. SLM1/2 are localized to
both the plasma membrane and eisosomes, structures composed of
Fig. 8. ARF6 inhibition enhances the
anti-neoplastic effects of synthetic
sphingolipids. (A) Viability of SupB15
cells treated with FTY720 (5 µM), SecinH3
(30 µM) or both. (B-E) Viability of different
cell lines treated with 893 (4 µM), SecinH3
(30 µM) or a combination. (B) SW620 cells
at 120 h. (C) PC3 cells at 144 h. (D) MCF7
cells at 120 h. (E) MDA-MB-231 cells at
96 h. (F) MDA-MB-231 cells at 96 h treated
with 893 (4 µM) and NAV2729 (6.25 µM).
(G) Peripheral blood mononuclear cell
(PBMC) colony formation assay at the
indicated doses of 893 and SecinH3.
Means±s.e.m. shown for n≥3 in all panels.
Using two-tailed t-test (A) or ordinary one-
way ANOVA (B-G) to compare with
controls: n.s., not significant; *P≤0.05;
**P≤0.01; ***P≤0.001. Tukey’s test was
used to correct for multiple comparisons
in B-G; statistics are relative to the
respective control.
11
RESEARCH ARTICLE Journal of Cell Science (2018) 131, jcs213314. doi:10.1242/jcs.213314
Jo
u
rn
al
o
f
Ce
ll
Sc
ie
n
ce
multiple BAR domain proteins that promote membrane tubulation
and endocytosis (Olivera-Couto et al., 2011). Intriguingly, expression
of yeast eisosomeproteins inCOS-7 cells resulted in a tubular staining
pattern highly reminiscent of the MICAL-L1-positive TRE (Olivera-
Couto et al., 2011). While the precise molecular relationships
between the yeast and mammalian sphingolipid-responsive pathways
are not yet clear, it is interesting to speculate that the eisosome
endocytic recycling pathway is paralleled in mammalian cells by the
ARF6-dependent TRE.
Although overexpression of a phosphomimetic mutant of GRP1
(GRP1-DD) rescued from both sphingolipid-induced nutrient
transporter downregulation and loss of the MICAL-L1-positive
TRE (Fig. 7A,B), other ARF6 regulatory proteins may be affected
by sphingolipids (Fig. 7C). For example, RAB35-GTP negatively
regulates ARF6 activity by recruiting the ARF6 GAPACAP2 to the
recycling endosome (Chesneau et al., 2012; Kobayashi and Fukuda,
2012; Rahajeng et al., 2012). RAB35 activation also leads to the loss
of MICAL-L1-positive tubular endosomes similar to what was
observed in sphingolipid-treated cells (Fig. 3C-F and Fig. 4A)
(Rahajeng et al., 2012). However, using a published RAB35 effector
pull-down assay (Chesneau et al., 2012), we were unable to detect
reproducible changes in RAB35-GTP levels following sphingolipid
treatment (not shown). This negative result is consistent with our
finding that ACAP2 siRNA did not restore ARF6-GTP levels or
CD98 trafficking in sphingolipid-treated cells (not shown). Wewere
unable to demonstrate that PP2A activation is necessary for
sphingolipid-induced ARF6 inactivation. However, the inability of
C2-dihydroceramide to activate PP2A (Chalfant et al., 2004; Kim
et al., 2016) or trigger trafficking disruptions associated with ARF6
inactivation, our finding that the non-sphingolipid small molecule
PP2A activator perphenazine (PPZ) recapitulates phenotypes
associated with ARF6 inactivation and the selective protection
from sphingolipid-induced phenotypes by a phosphomimetic GRP1
mutant all provide support for the model shown in Fig. 7C.
ARF6 has multiple pro-oncogenic roles, and establishing a
connection between tumor suppressive sphingolipids and this
GTPase has implications beyond the effects on nutrient
transporter trafficking. ARF6 activity is important for primary
tumor growth in some models, although the mechanism is
incompletely defined and may vary with tumor type. ARF6 is
activated downstream of a variety of receptor tyrosine kinases that
drive tumor growth (Hongu et al., 2015; Hu et al., 2013; Li et al.,
2017; Morishige et al., 2008). ARF6 promotes recycling of the
MET receptor tyrosine kinase (Parachoniak et al., 2011), and thus
decreasing ARF6-GTP may reduce MET surface levels with
important consequences for the highly invasive MET-driven
cancers like hereditary kidney cancers, sporadic papillary renal
cancer, hepatocellular carcinoma, and gastric cancer (Boccaccio and
Comoglio, 2006; Danilkovitch-Miagkova and Zbar, 2002). MET
and ARF6 promote tumor angiogenesis by stimulating β1-integrin
recycling in a GRP1-dependent manner (Hongu et al., 2015).
Melanoma and lung tumor isograft growth is compromised in mice
lacking ARF6 selectively in endothelial cells, and treatment with the
cytohesin inhibitor SecinH3 limited tumor growth and blocked
angiogenesis in vivo (Bill et al., 2012; Hongu et al., 2015). SecinH3
has also been shown to limit primary tumor growth in other
situations, including breast cancer and colorectal cancer models
(Pan et al., 2014; Zhao et al., 2016). The structurally unrelated
allosteric ARF6 inhibitor NAV-2729 was recently shown to inhibit
tumor growth in a uveal melanoma model (Yoo et al., 2016). These
studies with small-molecule ARF6 inhibitors indicate that ARF6 is
an actionable target in cancer. The results presented here suggest
that endogenous sphingolipids and sphingolipid-like small
molecules such as 893 may selectively kill cancer cells in part
through ARF6 inactivation (Fig. 8; Kim et al., 2016). Moreover,
sphingolipid-like agents or chemotherapies that increase ceramide
generation (Dimanche-Boitrel et al., 2011; Morad and Cabot, 2013;
Ogretmen and Hannun, 2001, 2004) may be even more effective
when used in combination with SecinH3 or NAV-2729.
ARF6 also has a well-documented role in metastasis in breast
cancer, melanoma and clear-cell renal carcinoma (Grossmann et al.,
2013; Hashimoto et al., 2004, 2016; Hu et al., 2013; Loskutov et al.,
2015; Morishige et al., 2008; Muralidharan-Chari et al., 2009a,b;
Tague et al., 2004; Yoo et al., 2016). Invadopodia are actin-rich
cellular protrusions enriched with various matrix proteases that
form cell-ECM contacts for matrix degradation and subsequent
tumor cell intravasation into the vasculature (Paz et al., 2014). ARF6
activity is required for invadopodia formation and subsequent
localized matrix degradation (Hashimoto et al., 2004). Membrane-
tethered membrane type 1-matrix metalloproteinase (MT1-MMP) is
secreted from cancer cells and promotes metastasis secondary to
collagen breakdown (Marchesin et al., 2015; Paz et al., 2014; Sodek
et al., 2007). ARF6 activity promotes recycling ofMT1-MMP to the
plasma membrane for release to the extracellular matrix (Loskutov
et al., 2015; Marchesin et al., 2015). Lastly, tumor-derived
microvesicles can promote angiogenesis, immune suppression,
tumor invasion and metastasis (D’Souza-Schorey and Clancy,
2012). ARF6 activation also promotes the release of microvesicles
containing matrix proteases such as MT1-MMP (Muralidharan-
Chari et al., 2009b). Given the multifaceted roles of ARF6 in tumor
cell invasion and metastasis, whether ceramide and synthetic
sphingolipids such as 893 limit metastasis as a consequence of
ARF6 inactivation merits further evaluation.
MATERIALS AND METHODS
Cell culture
SupB15, MDA-MB-231, SW620 and PC3 cells were obtained from the
ATCC. Normal, non-transformed hematopoietic FL5.12 cells were obtained
from Craig B. Thompson (Memorial Sloan Kettering Cancer Center,
New York, NY, USA), HeLa cells from Steve Caplan (University of
Nebraska Medical Center, Omaha, NE, USA) and MCF7 cells from the
Translational Oncology Research Laboratory at UCLA (University of
California Los Angeles, Los Angeles, CA, USA). PBMCs were obtained
through the CTSA-supported Institute for Clinical and Translational Science
at UCI under IRB protocols 2015-1883 (Edinger) and 2001-2058 (ICTS).
FL5.12 and SupB15 cells were maintained in RPMI 1640 supplemented
with 10% fetal bovine serum (FBS), 10 mM HEPES, 55 µM
β-mercaptoethanol, 2 mM L-glutamine and 1% antibiotics. FL5.12
medium was additionally supplemented with 500 pg/ml recombinant
murine IL-3. HeLa cells were maintained in DMEM with 4.5 g/l glucose
and L-glutamine supplemented with 10% FBS and antibiotics. MDA-MB-
231 and SW620 cells were cultured in DMEM containing 4.5 g/l glucose
and L-glutamine supplemented with 10% FBS, 1 mM sodium pyruvate and
antibiotics. PC3 cells were cultured in F12-K medium supplemented with
10% FBS and antibiotics. MCF7 cells were cultured in RPMI 1640
supplemented with 10% FBS and 1% antibiotics. Cells were screened for
Mycoplasma contamination at least every 6 months using the LookOut
Mycoplasma PCR Detection Kit (Sigma, Cat# MP0035-1KT); the cell lines
utilized in this study tested negative in all screens.
Antibodies
Antibodies were purchased from BD Biosciences (PE Rat IgG1 κ isotype
Cat #551979, flow cytometry 1:400 dilution; unconjugated anti-mouse
CD98 Cat #557479, flow cytometry 1:400 dilution; unconjugated anti-
human CD98 Cat #556074, flow cytometry and IF 1:100 dilution;
unconjugated Mu IgG1 κ isotype Cat #554121, flow cytometry 1:100
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dilution; PE anti-human CD98 Cat #556077, flow cytometry 1:100 dilution;
PE Mu IgG1 κ isotype Cat #555749, flow cytometry 1:100 dilution;
transferrin Receptor/CD71 Cat# 555534, IF 1:100 dilution); Biolegend (PE
anti-mouse CD98, Cat #128208, flow cytometry 1:400 dilution;
unconjugated anti-mouse CD98, Cat #128202, flow cytometry 1:400
dilution); Cell Signaling Technology (ARF6 Cat #5740, WB 1:1000
dilution; HA-tag Cat #2367, WB 1:1000, IF 1:100 dilution; EEA1 Cat#
3288, IF 1:100 dilution; Lamp1 Cat# 9091, IF 1:200 dilution; GM130
Cat#12480, IF 1:100 dilution); Novus Biologicals (MICAL-L1 Cat#
H00085377-B01P, IF 1:100 dilution, WB 1:1000 dilution; GLUT1 Cat#
NB300-666, IF 1:100 dilution); LI-COR (IRDye 800CW Gt-α-Rb Cat
#92632211, WB 1:10,000 dilution; IRDye 680LT Gt-α-Mu Cat #926-
68020, WB 1:10,000 dilution; IRDye 800CW Dk-α-Gt Cat #926-32214,
WB 1:10,000 dilution; IRDye 800CW Gt-α-Mu Cat #926-32210, WB
1:10,000 dilution; IRDye 800CW Gt-α-Rt Cat #926-32219, WB 1:10,000
dilution; IRDye 680LT Dk-α-Rb Cat #926-68023, WB 1:10,000 dilution);
BIO-RAD (TGN46 Cat #AHP500G, IF 1:100 dilution); Invitrogen (Alexa
Fluor 488 goat anti-mouse IgG Cat #A-11029, IF 1:200 dilution; Alexa
Fluor 488 goat anti-rabbit IgG Cat #A-11008, IF 1:200 dilution; Alexa Fluor
488 donkey anti-sheep IgG Cat #A-11015, IF 1:200 dilution; Alexa Fluor
594 goat anti-mouse IgG Cat #A-11032, IF 1:200 dilution; Alexa Fluor 594
donkey anti-mouse Cat #A-21203, IF 1:200 dilution; Alexa Fluor 594 goat
anti-rabbit Cat #R37117, IF 1:200 dilution).
Chemicals
C2-ceramide (VWR Cat #89164-564); dihydro-C2-ceramide (VWR Cat
#89164-568); FTY720 (Fisher Cat #50148635); cantharidin (VWR Cat
#89147-162); calyculinA (VWR Cat #89157-750); tautomycin (VWR Cat
#89149-880); YM201636 (Cayman Chemical Cat #13576); SecinH3
(Cayman Chemical Cat #10009570); NAV2729 (Tocris Cat #5986). The
enzyme bacterial sphingomyelinase (bSMase) was derived from S. aureus
(Sigma Cat #S8633). SH-BC-893 (893) and the lactam version (893-lactam)
were synthesized in Dr. Stephen Hanessian’s lab at University of Montreal
or by IntelliSyn RD, Montreal, Quebec, Canada.
Plasmids and transfection
GFP-tagged MICAL-L1 was a gift from Dr Steve Caplan (University of
Nebraska Medical Center, Omaha, NE, USA); pCDNA3-HA-ARF6-WT,
-ARF6-Q67L and -ARF6-T27N were generously provided by Julie
Donaldson (NIH, Bethesda, USA). pEF6-Myc-GRP1-WT and -GRP1-
S155D/T240D were gifts from Dr Victor W. Hsu (Harvard Medical School,
Boston, MA, USA). Transient transfections were performed using a calcium
phosphate transfection protocol as lipid transfection reagents interfere with
the cellular response to sphingolipids (not shown).
Confocal microscopy
Microscopy samples were prepared by plating cells on glass coverslips,
upon which cells were treated, fixed with 4% paraformaldehyde [10 min,
room temperature (RT)], then permeabilized and blocked with block
solution (10% FCS, 0.3% saponin, azide in PBS) (30 min, 37°C).
Coverslips were incubated in block solution with primary antibody
overnight, rocking, at 4°C, then washed once with wash solution (0.03%
saponin and azide in PBS), twice with PBS, and incubated in secondary
antibody at RT for 1 h while rocking. Cells were again washed, incubated in
1 mg/ml DAPI in wash solution, washed and mounted on slides using
Vectashield Mounting Medium (Vector Laboratories, Cat #H-1000).
Confocal microscopy images were collected with Zeiss LSM780 confocal
microscope with Plan-Apochromat 63×/1.40 Oil DIC or Plan-Apochromat
100×/1.40 Oil DIC objectives and using Zeiss ZEN digital imaging
software. ImageJ software was used for image processing. All images were
collected with the same microscope and image processing settings.
Cytoplasmic intensity in Fig. 6B and G was measured using ImageJ. A
region of interest (ROI) beneath the plasma membrane and excluding the
nucleus was selected and the mean gray value (MGV) measured.
Fluorescence intensity is expressed as the MGV within the ROI
after subtracting the background MGV. To measure the percentage of
cells containing tubular MICAL-L1 staining (Fig. 3D, Fig. 6F, Fig. S7B),
at least 20 different fields of view containing between 5 and 10 cells each
were measured.
Flow cytometry
Viability was measured by vital dye exclusion using 1 mg/ml DAPI. For
CD98 surface staining, 50,000-200,000 cells were incubated for 30 min on
ice with primary antibody diluted in FACS block (10% FBS and 0.05%
NaN3 in PBS). Cells were washed twice with FACS wash (2% FBS and
0.05% NaN3 in PBS) and suspended in FACS wash containing 1 mg/ml
DAPI. Analysis was restricted to live cells. For the transferrin internalization
assay, 100,000 cells were incubated on ice for 1 h with biotinylated
transferrin (100 µg/ml, Thermo Fisher Cat #T23363) in blocking buffer (1%
BSA in PBS). Cells werewashed twice with blocking buffer, resuspended in
complete growth medium on ice, and warmed to 37°C for the indicated
intervals. Following internalization, cells were fixed with 1%
paraformaldehyde and stained with APC-tagged streptavidin (Thermo
Fischer, Cat #SA1005). For the transferrin recycling assay, cells were
incubated with vehicle or FTY720 (5 µM) and Alexa Fluor 488-transferrin
(1 µg/ml; Life Technologies, Cat #T13342). Following internalization, cells
were resuspended in vehicle or FTY720 without transferrin for the indicated
intervals. Surface transferrin was stripped with pH 5.0 buffer. Samples were
evaluated on a Becton Dickinson LSRII flow cytometer.
Measurement of ARF6-GTP levels
ARF6-GTP was quantified as previously described (Cohen and Donaldson,
2010). Briefly, pGEX plasmid expressing GST (control) or GST-VHS-GAT
(effector pull-down construct) was transformed into BL21 cells. Protein
expression was induced with IPTG (0.6 mM). Proteins were isolated using
glutathione Sepharose 4B beads (Sigma-Aldrich, Cat #17-0756-01). Protein
was quantified using a BCA assay (Thermo Scientific Cat #23223).
Depending on ARF6 protein expression level, 50-200 µg cell lysate protein
was combined with 40 µg of GST-bound or GST-GGA3-VHS-GAT-bound
beads and rocked at 4°C for 1 h. Beads were washed three times with lysis
buffer and protein eluted in 10 µl 2× NuPAGE loading buffer. Total ARF6
protein levels were evaluated using 10% of the pull-down lysate.
Western blotting
Cell lysates were prepared in Triton X-100 or RIPA lysis buffer containing
1× complete protease inhibitor (Roche, Cat #11697498001 or Pierce, Cat
#88265). Protein concentration was quantified using Pierce BCA protein
assay (Thermo Scientific, Cat #23223). Western blot samples were prepared
in 1× NuPAGE sample buffer (Invitrogen, Cat #NP0007) supplemented
with 1× protease inhibitor and 50 mMDTT. Samples were run on Invitrogen
NuPAGE 4-12% Bis-Tris Gels (Cat #NP0336BOX) and transferred to
BioTrace NT nitrocellulose membrane (Pall, Cat #66485). Nitrocellulose
blots were incubated in blocking solution (5% bovine serum albumin,
0.05% NaN3 in 1× TBST) for 1 h then incubated overnight at 4°C in
blocking solution containing primary antibody at the recommended
dilution. Blots were washed three times in 1× TBST (TBS with 0.1%
Tween 20), incubated at RT for 1 h in blocking solution containing
secondary antibody (1:10,000), then washed three times in TBST. Blots
were imaged and quantified using a LI-COR Odyssey SA imaging system.
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